Valsartan / sacubitril

Active substance Valsartan / sacubitril
Domain Cardiovascular diseases
Reason of inclusion in Horizonscan Geneesmiddelen Indication extension
Main indication Other medication for cardiovascular diseases
Extended indication Post acute Myocardial Infarction


Proprietary name Entresto
Manufacturer Novartis
Mechanism of action Combination therapy
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)
Additional comments Entresto vertoont het werkingsmechanisme van een angiotensinereceptor-neprilysine-remmer door tegelijk neprilysine (neutrale endopeptidase, NEP) te remmen via LBQ657, de werkzame metaboliet van de prodrug sacubitril, en door de angiotensine II type 1-receptor (AT1-receptor) te blokkeren via valsartan.


Registration route Centralised (EMA)
Submission date November 2021
Expected Registration November 2022
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found
Frequency of administration 2 times a day

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Cost 1,800
Additional comments € 2,49 per tablet. Voor behandeling op jaarbasis: €1.815,95.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions Verwachte registratie HFpEF :2020, verwachte registratie MI: 2021.
References Fabrikant (nov 2017)

Other information

There is currently no futher information available.